the 2019 novel Corona virus (COVID-19). COVID-19 confirmed by laboratory testing.
Conditions
Interventions
Intervention 1: Intervention group: In addition to the standard care recommended by the National Committee, an initial dose of 2mg/kg will be started for all patients in the case group. The patients w
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: RT-PCR documented SARS-CoV-2 carriage in a nasopharyngeal and oropharyngeal sample at admission Age over 18 years old O2 saturation of less than 92 in room air Hospitalized patients
Exclusion criteria
Exclusion criteria: A known contraindication to treatment with the steroid Breastfeeding and pregnant patients Uncontrolled diabetes mellitus Uncontrolled hypertension patients who had previously been treated with steroids for any reason O2 Saturation of above 92 in room air Dissatisfaction with the study enrollment Immunodeficiency disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The all-cause mortality in 28 days. Timepoint: 28 days. Method of measurement: Clinical follow-up.;Clinical status. Timepoint: 5 and 10 days after intervention. Method of measurement: 9-points WHO ordinal scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Intubation and need for ventilation, and also admission to ICU. Timepoint: 5 and 10 days after intervention. Method of measurement: Clinical follow-up.;Duration of hospital admission. Timepoint: 5 and 10 days after intervention. Method of measurement: Clinical follow-up. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mohsen Moghadami
Shiraz University of Medical Sciences
Outcome results
None listed